ALEGRITEN contains the active substance anagrelide. ALEGRITEN is a drug that interferes with the development of platelets. It reduces the number of platelets produced by the bone marrow, resulting in a decrease in the number of platelets in the blood close to normal. Therefore, it is used in the treatment of patients with essential thrombocythemia.
Essential thrombocythemia is a condition that occurs when the bone marrow produces too many blood cells known as platelets. A high number of platelets in the blood can cause serious problems with blood circulation and blood clotting.